The revelation that this biotech may be on borrowed time is a great reminder to investors to analyze balance sheets.
News & Analysis: Synergy Pharmaceuticals
Shares collapse after management provides investors with a series of troubling business updates. Here's the must-know information for shareholders.
The small-cap biopharma reported second-quarter 2018 earnings and two important business updates.
The company delivered some welcome news to investors.
The company's making inroads with its first commercial-stage drug, but expenses could present big headwinds.
Investor presentations at conferences this week boosted optimism that Trulance is gaining market share.
Shares tumble after the company reports a higher-than-expected loss in the second quarter.
It was a quiet month for the commercial-stage biopharma, but that didn't stop its shares from tumbling.
Izzy Englander bought more shares of Gilead Sciences, Synergy, and Valeant during the first quarter. Why is the billionaire so bullish about these drug stocks?
An upgrade from a Wall Street research firm is boosting optimism in this small-cap biotech stock.